• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    12/13/24 7:18:17 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CERO alert in real time by email
    SC 13G 1 d815629dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

     

    CERo Therapeutics Holdings, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    58953M106

    (CUSIP Number)

      December 10, 2024  

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 58953M106

     

     1.   

     Names of Reporting Persons

     

     Lawrence Corey

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC USE ONLY

     

     4.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.   

     Sole Voting Power

     

     8,529,316 shares(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     8,529,316 shares(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,529,316 shares(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     5.7%(2)

    12.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    Includes (1) 8,454,339 shares of Common Stock held directly by Lawrence Corey and (2) 74,977 shares of Common Stock issuable upon the exercise of warrants exercisable within 60 days of December 10, 2024.

    (2)

    The percentage was based on 150,312,572 shares of Common Stock that were outstanding as of November 19, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q/A as filed with the SEC on November 20, 2024.


    Item 1(a).    Name of Issuer: CERo Therapeutics Holdings, Inc.
    Item 1(b).    Address of Issuer’s Principal Executive Offices: 201 Haskins Way, Suite 230, South San Francisco, CA 94080
    Item 2(a).    Name of Person Filing: Lawrence Corey
    Item 2(b).   

    Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Person is:

     

    8033 SE 45th Street

    Mercer Island, WA 98040

    Item 2(c).    Citizenship: Lawrence Corey is a U.S. citizen.
    Item 2(d).    Title of Class of Securities: Common Stock
    Item 2(e).    CUSIP Number: 58953M106
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)     

    ☐   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

    (b)     

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)     

    ☐   Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

    (d)     

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e)     

    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f)     

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)     

    ☐   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    (h)     

    ☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)     

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)     

    ☐   A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)     

    ☐   Group, in accordance with §240.13d–1(b)(1)(ii)(K).

       If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:    
    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.
    (a)      Amount Beneficially Owned: See Row 9 of cover page for Reporting Person.
    (b)      Percent of Class: See Row 11 of cover page for Reporting Person
    (c)      Number of shares as to which the person has:

     

       (i)    Sole power to vote or to direct the vote: See Row 5 of cover page for Reporting Person.
       (ii)    Shared power to vote or to direct the vote: See Row 6 of cover page for Reporting Person.
       (iii)    Sole power to dispose or to direct the disposition of: See Row 7 of cover page for Reporting Person.
       (iv)    Shared power to dispose or to direct the disposition of: See Row 8 of cover page for Reporting Person.
    Item 5.    Ownership of 5 Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.


    Item 6.    Ownership of More than 5 Percent on Behalf of Another Person
    Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
    Not applicable.
    Item 8.    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.    Notice of Dissolution of a Group
    Not applicable.
    Item 10.    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    December 13, 2024

    Date

    /s/ Lawrence Corey

    Lawrence Corey
    Get the next $CERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Laporte Kathleen

      4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

      6/2/25 5:09:45 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Byrnes Michael

      4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

      6/2/25 5:08:19 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rolfe Lindsey

      4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

      6/2/25 5:06:49 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    SEC Filings

    See more
    • SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.

      424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

      6/6/25 4:54:48 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

      6/6/25 8:33:03 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

      6/2/25 4:22:10 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

      SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

      12/13/24 7:18:17 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CERo Therapeutics Holdings Inc.

      SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

      11/20/24 4:06:55 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

      SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

      11/20/24 4:01:41 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

      SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the "Investors") pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued

      6/6/25 8:15:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

      Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying  mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by  the Europe

      6/2/25 9:05:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

      SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million (the "Equity Rule") On May 7, 2025 the Nasdaq Hearings Panel (the "Panel") notified the Company that following the execution of its private placement of Series D Preferred Stock on 4/21/2025, a partial drawdown from the Company's Equity Line of Credit, and the closing of a public of

      5/8/25 8:15:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Leadership Updates

    Live Leadership Updates

    See more
    • CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

      SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) --   CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO.  Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution. 

      12/6/24 9:00:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care